60
Participants
Start Date
May 1, 2022
Primary Completion Date
May 1, 2025
Study Completion Date
May 1, 2025
liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle."
NOT_YET_RECRUITING
Beijing Hospital, Beijing
NOT_YET_RECRUITING
Beijing Luhe Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
China-Japan Friendship Hospital, Beijing
RECRUITING
Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
Peking University First Hospital, Beijing
Collaborators (1)
CSPC Ouyi Pharmaceutical Co., Ltd.
INDUSTRY
Peking Union Medical College Hospital
OTHER